Skip to main content
. Author manuscript; available in PMC: 2022 Jan 31.
Published in final edited form as: Curr Alzheimer Res. 2018;15(7):637–642. doi: 10.2174/1567205015666180411092551

FIGURE 2.

FIGURE 2.

Saline soluble monomeric Aβ42 in control and melatonin treated mice. Brain and lymph node homogenates in saline along with plasma (B) from Tg2576 mice were evaluated by a sensitive and specific ELISA assay as shown for figure 1. The n values for control (Con) and melatonin (Mel)-treated samples from 4 and 15.5 month-old animals are listed in order for lymph node (n=3, 6, 16, 16); plasma (n=3, 5, 14, 28) and brain (n=3, 2, 13, 14). Aβ40 oligomers measurements in brain at 15.5 age months are also shown in controls and after treatment with melatonin (n= 8; 15). As shown in figure 1, Aβ42 oligomers measurements in brain are shown at 15.5 age months in controls and after treatment with melatonin (n=8; 15). Con = Control mice. Mel = Melatonin treated mice. As mentioned for figure 1, acceptable and consistent Aβ42 oligomer standards are not available to establish curves; thus, we have compared the relative luminescence values detected in brain extracts from control and melatonin-treated mice. As with Aβ40, oligomeric Aβ42 was not detectable in plasma or in lymph nodes.